5-甲基-3-氰基噻吩 | 41727-33-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 中文名称: 5-甲基-3-氰基噻吩
• 英文名称: 2-methyl-4-cyanothiophene
• 英文别名: 4-Cyano-2-methyl-thiophen；5-methylthiophene-3-carbonitrile
• CAS: 41727-33-7
• 化学式: C₆H₅NS
• 分子量: 123.178
• InChiKey: ZZEFHDRVGBYNKP-UHFFFAOYSA-N

物化性质

• 沸点：
  221.1±20.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  52
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  5-甲基-3-氰基噻吩 在 lithium diisopropyl amide 、 碘 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 以6.9 g的产率得到2-iodo-5-methylthiophene-3-carbonitrile
  参考文献：
  名称：

  一类抑制RNA解旋酶DHX33的多环化合物

  摘要：

  本发明涉及一类抑制RNA解旋酶DHX33的多环化合物。特别地，本发明涉及式I所示的化合物或其药学上可接受的形式、包含其的药物组合物、其制备方法、及其用于预防和/或治疗DHX33相关疾病的医药用途。

  公开号：

  CN112661754B
• 作为产物：
  描述：

  4-溴-2-甲基噻吩 、 氰化亚铜 以 N-甲基吡咯烷酮 为溶剂， 反应 20.0h， 以84%的产率得到5-甲基-3-氰基噻吩
  参考文献：
  名称：

  HIV Integrase Inhibitors

  摘要：

  这项发明涵盖了一系列公式I的双环嘧啶酮化合物，这些化合物抑制HIV整合酶并防止病毒整合到人类DNA中。这种作用使得这些化合物对治疗HIV感染和艾滋病有用。该发明还涵盖了用于治疗HIV感染者的药物组合物和方法。

  公开号：

  US20080004265A1

文献信息

• [EN] COT MODULATORS AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS DE COT ET LEURS PROCÉDÉS D'UTILISATION
  申请人：GILEAD SCIENCES INC

  公开号：WO2020252151A1

  公开（公告）日：2020-12-17

  The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) of generic Formula (I) and methods of use and manufacture thereof.

  本公开涉及一般性地与Cot（癌症大阪甲状腺）的通用化学式（I）的调节剂，以及其使用和制造方法。
• [EN] PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP<br/>[FR] DERIVES DE PYRROLOPYRIMIDINE ET DE PYRROLOPYRIDINE A SUBSTITUTION PAR UN GROUPE AMINO CYCLIQUE
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2004058767A1

  公开（公告）日：2004-07-15

  An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc.[SOLUTION] A pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by the following formula [I]:has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

  本发明的一个目的是提供一种针对CRF受体的拮抗剂，该拮抗剂可作为治疗或预防剂用于CRF被认为参与的疾病，如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃病、药物依赖、癫痫、脑梗塞、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、皮肤炎、精神分裂症等疾病。[解决方案] 一种用下式[I]表示的含有环状氨基团的吡咯吡嘧啶或吡咯吡啶衍生物具有高亲和力对CRF受体，并对CRF被认为参与的疾病有效。
• [EN] PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRROLOPYRIMIDINE ET DE PYRROLOPYRIDINE SUBSTITUÉS PAR UN GROUPE AMINO CYCLIQUE SERVANT D'ANTAGONISTES DU CRF
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2006001511A1

  公开（公告）日：2006-01-05

  [PROBLEM TO BE SOLVED] An object of the present invention is to provide an antagonist against CRF receptors and/or an agonist for receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc. [SOLUTION] A pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by the following formula [I] has a high affinity for CRF receptors and/or δ receptors, and is effective against diseases in which CRF is considered to be involved.

  本发明的目的是提供一种针对CRF受体的拮抗剂和/或对受体的激动剂，作为治疗或预防与CRF有关的疾病的有效药物，如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃肠疾病、药物依赖、脑梗死、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、癫痫、皮肤炎、精神分裂症、疼痛等疾病。具有以下式[I]所示的带有环状氨基团的吡咯吡嘧啶或吡咯吡啶衍生物对CRF受体和/或δ受体具有高亲和力，并对与CRF有关的疾病有效。
• [EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL<br/>[FR] INHIBITEURS DU CANAL POTASSIQUE MÉDULLAIRE EXTÉRIEUR RÉNAL
  申请人：MERCK SHARP & DOHME

  公开号：WO2014085210A1

  公开（公告）日：2014-06-05

  The present invention provides compounds of Formula (I), and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

  本发明提供了式（I）的化合物及其药用可接受的盐，这些化合物是ROMK（Kir1.1）通道的抑制剂。这些化合物可用作利尿剂和/或钠利尿剂，并用于治疗和预防包括高血压、心力衰竭以及与过多盐分和水分潴留有关的疾病等医疗条件。
• [EN] PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH TETRAHYDROPYRIDINE AS CRF ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRROLOPYRIMIDINE ET DE PYRROLOPYRIDINE SUBSTITUÉS AVEC DE LA TÉTRAHYDROPYRIDINE COMME ANTAGONISTES DU CRF
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2006001501A1

  公开（公告）日：2006-01-05

  [PROBLEM TO BE SOLVED] An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc. [SOLUTION] A pyrrolopyrimidine or pyrrolopyridine derivative substituted with tetrahydropyridine represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

  【需要解决的问题】本发明的目的是提供一种CRF受体拮抗剂，作为治疗或预防CRF参与的疾病的药物，如抑郁症、焦虑症、老年痴呆症、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃肠疾病、药物依赖、脑梗死、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、癫痫、皮肤炎、精神分裂症、疼痛等。 【解决方案】下式[I]所表示的以四氢吡啶取代的吡咯吡嘧啶或吡咯吡啶衍生物，具有高亲和力的CRF受体，并对CRF参与的疾病有效。